Results 71 to 80 of about 2,668 (112)

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance. [PDF]

Antibiotics (Basel), 2023
Duda-Madej A, Viscardi S, Topola E.
europepmc   +1 more source

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae. [PDF]

Antimicrob Agents Chemother
Lavoie T, Sierra T, Daffinee K, Pogue JM, Achour B, LaPlante K.   +5 more
europepmc   +1 more source

Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis. [PDF]

Antimicrob Agents Chemother
Mohammad S, Al Namer Y, Rahimeh W, Albalas M, Almangour TA.   +4 more
europepmc   +1 more source

Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland. [PDF]

Eur J Clin Microbiol Infect Dis, 2023
Nordmann P, Bouvier M, Poirel L.
europepmc   +1 more source

Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection. [PDF]

J Pediatr Pharmacol Ther
Sano U, Meyers R, Hasan U, Smoke S.
europepmc   +1 more source

Genotypic Evolution of Klebsiella pneumoniae Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy. [PDF]

Emerg Infect Dis, 2023
Arcari G, Cecilia F, Oliva A, Polani R, Raponi G, Sacco F, De Francesco A, Pugliese F, Carattoli A.   +8 more
europepmc   +1 more source

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion. [PDF]

Antibiotics (Basel), 2023
Marino A, Campanella E, Stracquadanio S, Calvo M, Migliorisi G, Nicolosi A, Cosentino F, Marletta S, Spampinato S, Prestifilippo P, Stefani S, Cacopardo B, Nunnari G.   +12 more
europepmc   +1 more source

Meropenem/vaborbactam activity against carbapenem-resistant Klebsiella pneumoniae from catheter-related bloodstream infections. [PDF]

Front Cell Infect Microbiol
Sivori F, Francalancia M, Truglio M, Cavallo I, Pronesti C, Fabrizio G, Celesti I, Cazzani A, Furzi L, Pimpinelli F, Di Domenico EG.   +10 more
europepmc   +1 more source

Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence. [PDF]

Infect Dis Ther
Bassetti M, Giacobbe DR, Vena A, Poulakou G, Rossolini GM, Soriano A, Nicolau DP.   +6 more
europepmc   +1 more source

Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae. [PDF]

JAC Antimicrob Resist, 2023
Rogers TM, Kline EG, Griffith MP, Jones CE, Rubio AM, Squires KM, Shields RK.   +6 more
europepmc   +1 more source